Strong Revenue Growth
iRhythm achieved $147.5 million in revenue for Q3 2024, representing 18.4% growth year-over-year driven by record demand from existing accounts and new account openings.
International Expansion
iRhythm reached more than 10,000 registrations in a single quarter in the UK for the first time and launched in Austria, the Netherlands, Switzerland, and Spain.
FDA Clearance and Regulatory Progress
Received FDA clearance for the first of two 510(k)s related to the Zio AT system and subsequently cleared the second 510(k) submission during the call.
Digital Integration and Milestones
Celebrated 1 millionth patient registered for Zio Monitor and launched integration with Epic's Aura platform, potentially saving up to 75% of the time for EHR integrations.
Strategic Technology Licensing
Entered a technology licensing agreement with BioIntelliSense to incorporate medical-grade, connected, multi-sensor capabilities into ACM products for future iterations.